VERANasdaqPharmaceutical PreparationsFiscal year ends December 31
Vera Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$28.92+1.04 (+3.73%)
Close on Oct 19, 2026
- Market cap
- $2.08B
- P/E (TTM)
- –
- Dividend yield
- –
Vera Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Vera Therapeutics | Industry median |
|---|---|---|
| Market Cap | $2.08B | $166.30M |
| Enterprise Value | $1.58B | $88.19M |
| PB Ratio | 5.11 | 2.03 |
| P/TBV Ratio | 5.11 | 2.29 |
Income (trailing twelve months)
| Measure | Vera Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$415.76M | -$21.40M |
| Net Income | -$401.90M | -$22.46M |
| EBITDA | -$415.22M | -$16.91M |
| EPS (Diluted) | -$5.86 | -$0.83 |
Returns
| Measure | Vera Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -91.8% | -53.2% |
| Return on Assets (ROA) | -72.3% | -40.9% |
| Return on Capital Employed (ROCE) | -85.8% | -38.1% |
Balance sheet
| Measure | Vera Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $499.16M | $61.43M |
| Net Cash (Debt) | $499.16M | $15.35M |
| Net Cash Per Share | $6.93 | $0.66 |
| Equity (Book Value) | $407.76M | $49.09M |
| Book Value Per Share | $5.66 | $1.37 |
| Tangible Book Value | $407.76M | $23.52M |
| Working Capital | $479.17M | $76.81M |
Financial position
| Measure | Vera Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 10.92 | 3.34 |
| Quick Ratio | 10.33 | 2.44 |
| Interest Coverage | -55.18 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Vera Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$338.65M | -$12.35M |
| Capital Expenditures | -$258.00K | -$1.08M |
| Free Cash Flow | -$338.91M | -$20.22M |
| FCF Per Share | -$4.70 | -$0.42 |
Efficiency
| Measure | Vera Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.61M | -$703.34K |
| Employee Count | 249 | 74 |
Dividends and yields
| Measure | Vera Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -19.3% | -23.3% |
| FCF Yield | -16.3% | -8.72% |
Shares
| Measure | Vera Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 72,063,300 | 58,127,000 |
| Shares Change (YoY) | 12.2% | 10.9% |
| Float | 59,729,400 | 49,136,700 |
| Shares Held by Insiders | 17.1% | 11.6% |
| Shares Held by Institutions | 108.1% | 59.4% |
Scores
| Measure | Vera Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 5.89 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Vera Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.